Activated lymphocytes have a high level of
low density lipoprotein (
LDL) uptake as compared to resting lymphocytes, whereas
scavenger receptors for
acetylated LDL (Ac-
LDL) are expressed on limited number of immune cells, i.e., monocytes/macrophages. The endocytosis of
LDL and Ac-
LDL by mononuclear cells was studied during in vitro and in vivo
HIV infection, in order to use
LDL and Ac-
LDL as carriers of
antiviral and/or
immunomodulatory drugs towards lymphocytes and monocytes. The uptake of
LDL and Ac-
LDL was analyzed by cytofluorimetry.
LDL endocytosis in PHA/
IL2-activated lymphocytes was higher than in resting lymphocytes. In vitro
HIV infection of PHA/
IL2-activated lymphocytes did not alter the high
LDL endocytosis in lymphocytes. CD4+ and CD8+ cells. In a group of 12 symptomatic patients there was no alteration of
LDL endocytosis in lymphocytes, CD4 and CD8 lymphocytes. In another group of 23 individuals, the Ac-
LDL endocytosis mediated by CD14+ monocytes was unaltered in asymptomatic patients (n = 6) and in some symptomatic patients (n = 6, CD14+ cells > 100/mm3). On the contrary, in other symptomatic patients (n = 11, CD14+ cells < 100/mm3), the number of Ac-LDL+ CD14+ cells decreased, whereas their efficiency of Ac-
LDL endocytosis increased as compared to those of other HIV+ patients. In conclusion, the use of
lipoproteins as carriers to increase the
drug delivery to CD4+ lymphocytes and to CD14+ monocytes can be envisaged, since: (i) the
LDL endocytosis was not impaired in CD4 lymphocytes of HIV+ patients, and (ii) the Ac-
LDL uptake by monocytes was altered only in some patients of stage IV.